Quest Diagnostics has introduced a new flow cytometry measurable residual disease (MRD) blood test for myeloma, a cancer arising from abnormal plasma cells. The test aims to enhance ultra-sensitive ...

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to bone marrow biopsies. Quest Diagnostics has announced the launch of a novel ...

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. Quest Flow ...

Flow cytometry allows for the analysis of single cells in a population. This technique is analogous to microscopy, but instead of producing an image, a flow cytometer provides automated quantification ...